NASDAQ, CORT - Corcept Therapeutics
Corcept Therapeutics Incorporated is a pharmaceutical company headquartered in
Menlo Park, California engaged in the development of drugs for the treatment of
severe psychiatric and metabolic diseases. Our current focus is on the
development of drugs for disorders that are associated with a steroid hormone
called cortisol. Elevated levels and abnormal release patterns of cortisol have
been implicated in a broad range of human disorders. Our scientific founders are
responsible for many of the critical discoveries illustrating the link between
psychiatric and metabolic disorders and aberrant cortisol. Since our inception
in May 1998, we have been developing our lead product, CORLUX?, a glucocorticoid
receptor II, or GR-II, antagonist. CORLUX modulates the effect of cortisol by
selectively blocking the binding of cortisol to one of its two known receptors,
the GR-II receptor, also known as the Type II or GR receptor.
? Psychotic depression. ...
Read SEC Filing on NASDAQ.com »